Is HSIC a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Henry Schein (HSIC) rests on Mix shift toward specialty and technology: Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. The bear case rests on distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Analysts covering it publish targets from $64.00 to $110.00 against a $84.96 share price on November 16, 2026, so even the professionals disagree by 48% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

HSIC key stats

At $84.96 on November 16, 2026, Henry Schein (HSIC) has a market cap of $9.4B and a P/E of 23.3 on trailing earnings (14.1 on forward earnings).

Market cap
$9.4B
P/E (trailing)
23.3
P/E (forward)
14.1
EPS (trailing 12 months)
$3.65
Price to book
3.0
Beta
0.86

Market cap, P/E and yield are measured at the $84.96 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Henry Schein (HSIC)?

The last two weeks for Henry Schein, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • HSIC closed at $84.96 on November 16, 2026, down 3.9% over the past five trading days (from $88.41).
  • On November 16, 2026, Henry Schein filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 3, 2026, Henry Schein filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 3, 2026, Henry Schein filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 4, 2026, UBS raised its target to $95.00 from $94.00 (Neutral).
  • On November 4, 2026, Evercore ISI Group lowered its target to $100.00 from $105.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Henry Schein sells the products a dental office or a physician's practice consumes every day: consumables, small equipment, implants, orthodontic aligners, endodontic and biomaterial products, plus the software that runs the front desk and the billing. It reports in three pieces. Global Distribution and Value-Added Services is the large, low-margin core that moves other manufacturers' goods to roughly a million customers across dozens of countries. Global Specialty Products covers the higher-margin implant, orthodontic and biomaterials lines the company mostly bought. Global Technology sells practice-management and revenue-cycle software, including the Dentrix family, and carries by far the best economics in the company (segment operating margin of roughly 27% in Q2 2026 on segment operating income of about $49 million). Specialty and technology together contribute around half of operating income on a small fraction of revenue, which is the whole strategic point. The last three years have been unkind. A 2023 cyberattack knocked out ordering systems, dental patient traffic and equipment purchases stayed soft, and gross margins compressed through 2025. That drew in outside capital: KKR built a roughly 12% position in January 2025 and took two board seats, the standstill ceiling was later raised from 14.9% to 19.9%, and activist Ananym Capital pressed publicly for CEO succession, cost cuts and a review of the medical distribution business. Fred Lowery now runs the company against a restructuring and value-creation program targeting more than $200 million of margin improvement, with charges expected to run through 2027. Q2 2026 was the clearest sign it is working: sales of about $3.5 billion (up roughly 6.7%), internal local-currency growth of about 4.6%, non-GAAP EPS up about 15.5% to roughly $1.27, and raised full-year guidance. At roughly $9.9 billion of market value (a $86.84 share price on October 16, 2026) on about $13.6 billion of trailing revenue, the market is still paying a distributor's price for it, even after a ~13% gain in 2026 and ~40% over twelve months. The management bench is also changing. On October 8, 2026 the company named Emmanuel Caprais, CFO of ITT from 2020 to May 2026, as its next chief financial officer, effective November 4; Ronald South, CFO for the past four years, moves to a senior advisory role. The company also said it plans to add a Chief Strategy and Transformation Officer and a technology leader. Third-quarter results land on November 3, with consensus at ~$1.36 of adjusted EPS on ~$3.48 billion of sales.

The bull case: what would have to be true for $110.00

The most optimistic published target on HSIC is $110.00, +29.5% from the $84.96 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Mix shift toward specialty and technology.

Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. Management has been steering capital and acquisitions toward those two, and they now supply about half of operating income. Every point of mix shift moves consolidated margin more than any volume gain in core distribution can.

2. The value-creation and restructuring program.

The program launched in 2025 with KKR's involvement targets more than $200 million of margin improvement through pricing discipline, indirect procurement, private-label penetration and product mix. Q2 2026 gross margin reversed the compression seen through 2025, and non-GAAP operating margin improved roughly 25 basis points year over year. Restructuring charges are expected to continue into 2027, so reported results will keep lagging the adjusted numbers for a while. The incoming CFO, Emmanuel Caprais, and a planned Chief Strategy and Transformation Officer suggest management intends to run the program with new hires rather than only existing staff.

3. A recovering demand backdrop in dental and medical.

Internal local-currency growth accelerated from Q1 to Q2 2026, and the company raised full-year sales growth guidance to roughly 4.5% to 5.5%. Dental consumables track patient visits and medical distribution tracks office-based procedure volume, neither of which grows quickly, but both had been running below trend since 2023. A return to normal utilization is a meaningful swing factor for a business with this much operating leverage on fixed distribution costs. Consensus for 2026 sits at ~$13.9 billion of revenue and ~$5.39 of adjusted EPS, rising to ~$14.4 billion and ~$5.99 in 2027.

4. Governance pressure and portfolio decisions.

KKR sits on the board with a raised ownership ceiling, and Ananym has publicly argued for divesting medical distribution. Whether or not a divestiture happens, the presence of an engaged large holder raises the probability of buybacks, cost action and portfolio simplification being pursued faster than a founder-led board would have chosen. It also introduces the possibility of a structural transaction that the current valuation does not reflect.

The bear case: what would have to be true for $64.00

The most pessimistic published target is $64.00, -24.7% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Henry Schein is worth if the risks below bite instead of the drivers above.

Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Dental consumables and equipment demand depends on discretionary patient visits, and the softness that started in 2023 has not fully cleared. Tariffs and freight on imported dental and medical goods are a live cost input that cannot always be passed through quickly. The company has grown specialty and technology largely by acquisition, which carries integration risk and a large goodwill balance relative to equity. Manufacturers selling directly to practices, and pure-play e-commerce suppliers, continue to chip at the intermediary's role, and the 2023 cyberattack is a reminder of how concentrated the operational risk in an ordering platform can be. Leverage is not trivial either: Yahoo data show ~$3.8 billion of debt against ~$157 million of cash, and GAAP net margin of roughly 3% leaves little cushion. A CFO handover on November 4, 2026, the day after Q3 results, adds execution risk during the margin program.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HSIC already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on HSIC

15 analysts cover HSIC, with an average target of $96.60 (+13.7% against $84.96) and a split of 8 buy, 7 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HSIC forecast and price target page.

How is HSIC valued?

Market cap, P/E and dividend yield at today's price are in the HSIC key stats above. The business figures below come from Henry Schein's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$13.6B, up ~6.7% year over year in Q2 2026
  • Margins (TTM): ~31% gross, ~5.8% operating, ~3% net
  • Net income (TTM): ~$403M; GAAP EPS ~$3.43
  • FY2026 guidance, non-GAAP diluted EPS: ~$5.29 to ~$5.39
  • Price to trailing sales: ~0.73x
  • Next earnings: Nov 3, 2026; consensus EPS ~$1.36 on ~$3.48B

As of October 2026: At $86.84 against guided non-GAAP EPS of about $5.29 to $5.39, HSIC trades near 16 times this year's adjusted earnings and about 14.5 times next year's consensus, but roughly 25 times trailing GAAP earnings, because restructuring charges running through 2027 keep reported profit well below the adjusted figure. The sales multiple, under 0.75 times, matters least for a distributor. The gap between the GAAP and adjusted multiples is effectively the market's discount on whether the margin program sticks.

How do you decide if HSIC is a buy?

Whether HSIC is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold HSIC indirectly through an index or sector ETF before adding more.

What would change your mind on HSIC

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Mix shift toward specialty and technology stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the HSIC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HSIC against your real portfolio and see your actual exposure before deciding.

Your questions about Henry Schein

Ask Walnut's AI anything about HSIC and see how it fits what you own.

FAQ

Is HSIC a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Mix shift toward specialty and technology, with revenue (ttm) at ~$13.6B, up ~6.7% year over year in Q2 2026. The bear case rests on distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Analysts covering it are spread from $64.00 to $110.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell HSIC?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $64.00, -24.7% from the $84.96 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for HSIC?

+

Mix shift toward specialty and technology. Distribution is a pennies-on-the-dollar business, while the technology segment earns roughly 27% operating margins and specialty products earns well above the corporate average. The most optimistic analyst target on HSIC is $110.00, +29.5% from the $84.96 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for HSIC?

+

Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Dental consumables and equipment demand depends on discretionary patient visits, and the softness that started in 2023 has not fully cleared. Tariffs and freight on imported dental and medical goods are a live cost input that cannot always be passed through quickly. The company has grown specialty and technology largely by acquisition, which carries integration risk and a large goodwill balance relative to equity. Manufacturers selling directly to practices, and pure-play e-commerce suppliers, continue to chip at the intermediary's role, and the 2023 cyberattack is a reminder of how concentrated the operational risk in an ordering platform can be. Leverage is not trivial either: Yahoo data show ~$3.8 billion of debt against ~$157 million of cash, and GAAP net margin of roughly 3% leaves little cushion. A CFO handover on November 4, 2026, the day after Q3 results, adds execution risk during the margin program. The most pessimistic published target is $64.00, -24.7% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Henry Schein do?

+

The largest distributor of dental and medical supplies to office-based practices, plus specialty implants and Dentrix practice software.

What would have to change for HSIC to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Mix shift toward specialty and technology) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Henry Schein actually do?

+

It is a distributor. Henry Schein buys dental and medical products from thousands of manufacturers and resells them to office-based dentists and physicians, roughly a million customers worldwide, alongside its own specialty product brands (implants, orthodontics, biomaterials) and practice-management software such as Dentrix.

How do you invest in HSIC?

+

HSIC trades on the NasdaqGS, so any US brokerage that offers listed equities can hold it. It also sits inside broad health care and mid-cap indexes, so many investors already own a small slice through funds. In Walnut you can add HSIC to a basket alongside other health care distribution or dental names and give the group a stated thesis and target weights.

Is HSIC a dental stock or a medical stock?

+

Predominantly dental. Dental is the larger and more profitable side of the business and drives most of the sentiment on the stock, while medical distribution is a sizeable but low-margin second leg that activist investor Ananym has argued should be reviewed for divestiture.

Walnut is informational, not investment advice, and gives no verdict on HSIC. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks